Merck will submit a new Biologics License Application for ifinatamab deruxtecan to the FDA by October 10, 2026.
Posted 2026-09-26 — 14 days before the deadline, stated before the outcome.
The claim
Merck will submit a new Biologics License Application for ifinatamab deruxtecan to the FDA by October 10, 2026.
Reasoning trace
- Voluntary withdrawal is often a strategic pause to address regulatory concerns rather than a terminal failure.
- Joint development with Daiichi Sankyo implies shared financial incentive to continue the approval process.
- The drug targets a high-need oncology indication with limited existing options.
Evidence so far
0 confirming · 0 denying signals · 0 verified · 2 broken assumptions. The evidence itself is part of the full dossier.
Probability history
Updated 2 times since mint (last on 2026-09-26) — 80% at mint → 80% today.
The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].
Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.